These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 33357766)

  • 1. Liver targeted gene therapy: Insights into emerging therapies.
    Moscoso CG; Steer CJ
    Drug Discov Today Technol; 2019 Dec; 34():9-19. PubMed ID: 33357766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic editing of hepatocyte genome in vivo.
    Ruiz de Galarreta M; Lujambio A
    J Hepatol; 2017 Oct; 67(4):818-828. PubMed ID: 28527665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic-Based Approaches to Inherited Metabolic Liver Diseases.
    Zabaleta N; Hommel M; Salas D; Gonzalez-Aseguinolaza G
    Hum Gene Ther; 2019 Oct; 30(10):1190-1203. PubMed ID: 31347416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene editing and CRISPR in the clinic: current and future perspectives.
    Hirakawa MP; Krishnakumar R; Timlin JA; Carney JP; Butler KS
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32207531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Evolution of Gene Therapy in the Treatment of Metabolic Liver Diseases.
    Moscoso CG; Steer CJ
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32785089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
    Bryson TE; Anglin CM; Bridges PH; Cottle RN
    Yale J Biol Med; 2017 Dec; 90(4):553-566. PubMed ID: 29259521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Engineered Nucleases with Adeno-associated Viral Vectors for Therapeutic Gene Editing.
    Epstein BE; Schaffer DV
    Adv Exp Med Biol; 2017; 1016():29-42. PubMed ID: 29130152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-viral delivery of genome-editing nucleases for gene therapy.
    Wang M; Glass ZA; Xu Q
    Gene Ther; 2017 Mar; 24(3):144-150. PubMed ID: 27797355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
    Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
    Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Advances in Preclinical Developments Using Adenovirus Hybrid Vectors.
    Ehrke-Schulz E; Zhang W; Gao J; Ehrhardt A
    Hum Gene Ther; 2017 Oct; 28(10):833-841. PubMed ID: 28854818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 system: A new-fangled dawn in gene editing.
    Gupta D; Bhattacharjee O; Mandal D; Sen MK; Dey D; Dasgupta A; Kazi TA; Gupta R; Sinharoy S; Acharya K; Chattopadhyay D; Ravichandiran V; Roy S; Ghosh D
    Life Sci; 2019 Sep; 232():116636. PubMed ID: 31295471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.
    Villiger L; Grisch-Chan HM; Lindsay H; Ringnalda F; Pogliano CB; Allegri G; Fingerhut R; Häberle J; Matos J; Robinson MD; Thöny B; Schwank G
    Nat Med; 2018 Oct; 24(10):1519-1525. PubMed ID: 30297904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome editing: the road of CRISPR/Cas9 from bench to clinic.
    Eid A; Mahfouz MM
    Exp Mol Med; 2016 Oct; 48(10):e265. PubMed ID: 27741224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery Approaches for Therapeutic Genome Editing and Challenges.
    Ates I; Rathbone T; Stuart C; Bridges PH; Cottle RN
    Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 32977396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding the Toolbox and Targets for Gene Editing.
    Dan J; Memczak S; Izpisua Belmonte JC
    Trends Mol Med; 2021 Mar; 27(3):203-206. PubMed ID: 33487569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.